<DOC>
	<DOCNO>NCT00679289</DOCNO>
	<brief_summary>This study evaluate safety effectiveness combination regimen KW2871 high dose Interferon-alfa2b ( HDI ) patient metastatic melanoma ( skin cancer spread part body ) . KW2871 antibody make laboratory . Antibodies part immune system . KW2871 attach GD3 ganglioside ( molecule find melanoma cell ) . This may help slow stop growth melanoma tumor . Interferon-alfa 2b man-made version interferon . Interferons among number substance produce immune system response presence enemy cell . Not `` interfere '' foreign invader may cause infection , prevent growth spread diseased cell well , include type cancer cell . Interferons show effective variety tumor .</brief_summary>
	<brief_title>Phase II Study KW2871 Combined With High Dose Interferon-alpha2b Patients With Metastatic Melanoma</brief_title>
	<detailed_description>This open label study KW2871 plus high dose IFN-Î±2b ( HDI ) patient measurable metastatic melanoma . All eligible patient receive KW2871 IV every two week ( Wednesday ) start week 1 . HDI also give dose 20 MU/m2 IV five consecutive day ( Monday thru Friday ) per week four week , 10 MU/m2 sc three time week ( Monday , Wednesday , Friday ) . Patients treat KW2871-HDI combination therapy disease progression require treatment intervention would interfere interpretation study result .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . &gt; 18 year age 2 . Histologically proven metastatic cutaneous , mucosal , unknown primary melanoma 3 . Measurable disease use response evaluation criterion solid tumor RECIST criterion 4 . Are ambulatory ( ECOG performance status 0 1 ) expect survival &gt; /= 4 month 5 . Within last two week prior study day 1 , follow laboratory parameter within range specify ( Table 4 ) : Table 4 : Baseline peripheral laboratory value acceptable enrollment Hemoglobin &gt; /= 9 g/dL Platelets &gt; /= 100 x 109/L Neutrophil count &gt; /= 1.5 x 109/L INR &lt; /= 2.0 ( &lt; /=3.0 warfarin therapy ) Serum creatinine &lt; /=1.5 x upper limit normal Serum total bilirubin &lt; /=1.5 x upper limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; /= 2.5 x upper limit normal 6 . Able willing give valid write informed consent 1 . Other malignancy within three year prior study entry receive active treatment , except treat melanoma nonmelanoma skin cancer cervical breast carcinoma situ 2 . Mental impairment may compromise ability give informed consent comply study requirement 3 . Participation clinical trial involve chemotherapy , radiotherapy immunotherapy within four week prior study enrollment 4 . Prior exposure antiGD3 antibodies 5 . Pregnancy breastfeed 6 . Women childbearing potential refuse unable use effective mean contraception 7 . Active autoimmune disorder require systemic treatment immunomodulatory immunosuppressant medication ( i.e . corticosteroid , cyclophosphamide , methotrexate , biologics ) . Corticosteroids substitution dose allow 8 . Metastatic brain disease allow provided appropriate treatment administer ( surgery irradiation ) two month followup brain MRI show disease control ( stability regression ) 9 . Autoimmunerelated hypothyroidism vitiligolike depigmentation allow provided patient medically stable treatment ( thyroidhormone replacement observation ) 10 . Serious medical illness , cardiovascular disease [ uncontrolled congestive heart failure hypertension , active ischemic disease heart ( angina ) , recent ( &lt; 3 month ) myocardial infarction , severe cardiac arrhythmia ] , bleed disorder , obstructive restrictive pulmonary disease , active systemic infection require antibiotic , serious intercurrent illness require hospitalization , inflammatory bowel disorder , significant psychiatric disease , opinion principal investigator would prevent adequate inform consent render study treatment unsafe contraindicate . 11 . Subjects clinical suspicion HIV hepatitis undergo follow viral test : HIV ( human immunodeficiency virus ) : subject must negative antibody HBV ( hepatitis B virus ) : subject must negative antigen HCV ( hepatitis C virus ) : subject must negative test serum antibody If test positive patient exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>KW2871</keyword>
	<keyword>ecromeximab</keyword>
	<keyword>anti-ganglioside</keyword>
	<keyword>antibody</keyword>
	<keyword>interferon alpha</keyword>
	<keyword>Metastatic melanoma</keyword>
</DOC>